Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dow Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.7 (market cap $29.60B), while Dow Inc trades at $30.58 (market cap $22.58B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.48% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DOW | |
|---|---|---|
Market Cap | $29.60B | $22.58B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $41.87 |
52-Week Low | $205.48 | $20.65 |
Enterprise Value | $27.56B | $38.27B |
Dividend Yield | — | 4.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
DOW trades at $30.78, up 0.65% today, with a bullish technical signal and positive earnings beats in recent quarters. However, the company reported a net loss of $2.62 billion in 2025, with declining revenue and negative profit margins. Analyst consensus is a 'Hold' with a $35.11 price target, suggesting modest upside potential from current levels.
The outlook is mixed; earnings improvements and dividend payments provide support, but persistent losses and high debt pose risks. Investment opportunity hinges on a turnaround in profitability, while key risks include competitive pressures and macroeconomic headwinds affecting the chemicals sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
